DJS Antibodies

Executive Summary

DJS Antibodies is a UK-based biotechnology company founded in 2017 and headquartered in Oxford. The company specializes in discovering and developing antibody therapeutics targeting difficult-to-drug membrane proteins, particularly G protein-coupled receptors (GPCRs). Leveraging its proprietary platform, DJS generates functional antibodies for complex disease areas with high unmet medical need. Despite being a private company with limited disclosed financials, the platform has the potential to unlock challenging therapeutic targets, positioning DJS as a unique player in the antibody discovery space. The company’s focus on GPCRs, which are involved in numerous diseases yet remain under-addressed by conventional antibodies, underpins its value proposition and potential for future partnerships or licensing deals.

Upcoming Catalysts (preview)

• Q2 2027Pharmaceutical partnership or licensing deal leveraging GPCR platform40% success
• Q4 2026Series A funding round to advance pipeline into IND-enabling studies60% success
• Q1 2027Publication of preclinical proof-of-concept data for lead antibody candidate75% success